X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (16) 16
heterocyclic compounds (16) 16
humans (16) 16
metallurgy (16) 16
oncology (16) 16
organic chemistry (16) 16
human necessities (14) 14
hygiene (14) 14
index medicus (14) 14
medical or veterinary science (14) 14
preparations for medical, dental, or toilet purposes (14) 14
specific therapeutic activity of chemical compounds ormedicinal preparations (14) 14
carcinoma, non-small-cell lung - drug therapy (12) 12
female (12) 12
lung neoplasms - drug therapy (12) 12
male (12) 12
alectinib (10) 10
middle aged (10) 10
adult (7) 7
aged (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
chemotherapy (7) 7
lung neoplasms - pathology (7) 7
cancer (6) 6
carbazoles - therapeutic use (6) 6
crizotinib (6) 6
drug resistance, neoplasm (6) 6
nsclc (6) 6
piperidines - therapeutic use (6) 6
carbazoles - administration & dosage (5) 5
lung cancer (5) 5
lung cancer, non-small cell (5) 5
piperidines - administration & dosage (5) 5
treatment outcome (5) 5
analysis (4) 4
animals (4) 4
brain metastases (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
central nervous system (4) 4
disease (4) 4
lung neoplasms - genetics (4) 4
metastasis (4) 4
mice (4) 4
non-small cell lung carcinoma (4) 4
open-label (4) 4
patients (4) 4
pharmacology & pharmacy (4) 4
protein kinase inhibitors - administration & dosage (4) 4
protein kinase inhibitors - therapeutic use (4) 4
pyrazoles - therapeutic use (4) 4
pyridines - therapeutic use (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
safety (4) 4
alk (3) 3
alk inhibitor (3) 3
anaplastic lymphoma kinase (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic agents - therapeutic use (3) 3
biomarkers (3) 3
cancer research (3) 3
cancer therapies (3) 3
carbazoles - adverse effects (3) 3
carcinoma, non-small-cell lung - enzymology (3) 3
cell line, tumor (3) 3
cell proliferation - drug effects (3) 3
central nervous system neoplasms - secondary (3) 3
ceritinib (3) 3
ch5424802 (3) 3
dose-response relationship, drug (3) 3
histone deacetylase inhibitors (3) 3
hydroxamic acids - pharmacology (3) 3
lung neoplasms - enzymology (3) 3
medicine & public health (3) 3
models (3) 3
mutation (3) 3
non-small cell lung cancer (3) 3
non-small-cell lung cancer (3) 3
pharmacology/toxicology (3) 3
piperidines - adverse effects (3) 3
protein-tyrosine kinase (3) 3
respiratory system (3) 3
tumors (3) 3
alk g1269a mutation (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - chemical synthesis (2) 2
art (2) 2
article (2) 2
biological availability (2) 2
carbazoles - pharmacokinetics (2) 2
carbazoles - pharmacology (2) 2
cell lung-cancer (2) 2
central nervous system neoplasms - drug therapy (2) 2
chemistry, medicinal (2) 2
chemistry, organic (2) 2
comparative analysis (2) 2
confidence intervals (2) 2
criteria (2) 2
drug dosages (2) 2
enzyme inhibitors - chemical synthesis (2) 2
enzyme inhibitors - pharmacokinetics (2) 2
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (52) 52
French (5) 5
Spanish (4) 4
German (1) 1
Italian (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2018, Volume 82, Issue 1, pp. 129 - 138
Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated... 
Alectinib | Medicine & Public Health | ALK inhibitor | NSCLC | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Exposure response | HEALTHY-SUBJECTS | INHIBITOR ALECTINIB | ANTITUMOR-ACTIVITY | MODELS | DRUGS | BRAIN METASTASES | PHARMACOLOGY & PHARMACY | MUTATIONS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Carbazoles - administration & dosage | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Anaplastic Lymphoma Kinase - genetics | Dose-Response Relationship, Drug | Multicenter Studies as Topic | Female | Lung Neoplasms - genetics | Carbazoles - adverse effects | Piperidines - administration & dosage | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Protein Kinase Inhibitors - administration & dosage | Crizotinib - pharmacology | Gene Rearrangement | Piperidines - adverse effects | Anaplastic Lymphoma Kinase - biosynthesis | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Clinical Trials, Phase II as Topic | Lymphomas | Metabolites | Lung cancer, Non-small cell | Analysis | Statistical analysis | Cell survival | Small cell lung carcinoma | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Exposure | Regression analysis | Cancer therapies | Patients | Lymphoma | Confidence intervals | Statistical models | Safety | Hazard assessment | Protein-tyrosine kinase | Cancer | Tumors | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 30_suppl, pp. 22 - 22
22 Background: Erlotinib is an EGFR TKI established as maintenance, second- and third-line treatment in unselected NSCLC patients and as first-line treatment... 
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2017, Volume 79, Issue 3, pp. 559 - 568
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e20575 - e20575
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e89518
Journal Article
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 03/2016, Volume 77, Issue 3, pp. 623 - 628
Alectinib is a highly selective next-generation anaplastic lymphoma kinase (ALK) inhibitor. Although alectinib shows inhibitory activity against various... 
ALK | METASTASES | CH5424802 | CHEMOTHERAPY | Resistance mutation | Alectinib | LUNG-CANCER | ALK G1269A mutation | MODELS | ONCOLOGY | PHARMACOLOGY & PHARMACY | CRIZOTINIB RESISTANCE | Anaplastic lymphoma kinase | Lymphomas | Genetic aspects | Lung cancer, Non-small cell | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e20564 - e20564
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 05/2017, Volume 6, Issue 3, pp. 280 - 291
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2004, Volume 10, Issue 23, pp. 8094 - 8104
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2019, Volume 14, Issue 7, pp. 1233 - 1243
Introduction: At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib... 
ALEX | EML4-ALK | Alectinib | Non–small cell lung cancer | NGS | ONCOLOGY | RESPIRATORY SYSTEM | Non-small cell lung cancer | CRIZOTINIB
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 82, pp. 27 - 33
Journal Article